勘误：在中国血液透析患者中，用达贝泊汀α注射液替代促红细胞生成素α注射液治疗肾性贫血的疗效和安全性：一项随机、开放标签、平行组、非劣效性III期试验。
Corrigendum: Efficacy and safety of darbepoetin alfa injection replacing epoetin alfa injection for the treatment of renal anemia in Chinese hemodialysis patients: A randomized, open-label, parallel-group, noninferiority phase III trial.
出版信息
Chronic Dis Transl Med. 2023 Sep 19;10(4):350. doi: 10.1002/cdt3.94. eCollection 2024 Dec.
Abstract
[This corrects the article DOI: 10.1002/cdt3.23.].
摘要
[本文更正了文章的数字对象标识符：10.1002/cdt3.23。]
相似文献
1
Corrigendum: Efficacy and safety of darbepoetin alfa injection replacing epoetin alfa injection for the treatment of renal anemia in Chinese hemodialysis patients: A randomized, open-label, parallel-group, noninferiority phase III trial.勘误：在中国血液透析患者中，用达贝泊汀α注射液替代促红细胞生成素α注射液治疗肾性贫血的疗效和安全性：一项随机、开放标签、平行组、非劣效性III期试验。
Chronic Dis Transl Med. 2023 Sep 19;10(4):350. doi: 10.1002/cdt3.94. eCollection 2024 Dec.
2
Efficacy and safety of darbepoetin alfa injection replacing epoetin alfa injection for the treatment of renal anemia in Chinese hemodialysis patients: A randomized, open-label, parallel-group, noninferiority phase III trial.在中国血液透析患者中，达贝泊汀α注射液替代促红细胞生成素α注射液治疗肾性贫血的疗效与安全性：一项随机、开放标签、平行组、非劣效性III期试验。
Chronic Dis Transl Med. 2022 Apr 18;8(2):134-144. doi: 10.1002/cdt3.23. eCollection 2022 Jun.
3
Corrigendum: Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: A randomized, open-label, parallel-group, non-inferiority phase III trail.勘误：聚乙二醇化促红细胞生成素α注射液与促红细胞生成素α注射液治疗中国慢性肾衰竭血液透析患者贫血的随机、开放标签、平行组、非劣效性III期试验。
Chronic Dis Transl Med. 2023 Sep 19;10(1):81. doi: 10.1002/cdt3.93. eCollection 2024 Mar.
4
Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: A randomized, open-label, parallel-group, non-inferiority Phase III trail.聚乙二醇化促红细胞生成素α注射液与促红细胞生成素α注射液治疗中国慢性肾衰竭血液透析患者贫血的比较：一项随机、开放标签、平行组、非劣效性III期试验。
Chronic Dis Transl Med. 2022 Mar 29;8(1):59-70. doi: 10.1002/cdt3.13. eCollection 2022 Mar.
5
Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.聚乙二醇化促红细胞生成素α治疗血液透析患者贫血的随机对照试验。
Am J Kidney Dis. 2002 Jul;40(1):110-8. doi: 10.1053/ajkd.2002.33919.
6
Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly.乳腺癌化疗所致贫血的治疗：每2周使用200微克阿法达贝泊汀与每周使用40,000单位阿法依泊汀的随机对照试验结果
Clin Breast Cancer. 2005 Dec;6(5):446-54. doi: 10.3816/cbc.2005.n.050.
7
Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial.达普司他治疗初发透析患者慢性肾脏病贫血的疗效和安全性：一项随机临床试验。
JAMA Intern Med. 2022 Jun 1;182(6):592-602. doi: 10.1001/jamainternmed.2022.0605.
8
Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial.达普司他对比阿法达贝泊汀在日本血液透析贫血患者中的疗效和安全性：一项随机、双盲、3 期临床试验。
Clin J Am Soc Nephrol. 2020 Aug 7;15(8):1155-1165. doi: 10.2215/CJN.16011219. Epub 2020 Jul 28.
9
A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.每2周一次的达贝泊汀α与每周一次的促红细胞生成素α治疗乳腺癌、肺癌或妇科癌症患者化疗所致贫血的随机对照研究。
Oncologist. 2004;9(6):696-707. doi: 10.1634/theoncologist.9-6-696.
10
Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.罗沙司他（FG-4592）治疗维持性血液透析患者贫血的 2 期随机、6-19 周、开放标签、活性对照、剂量范围、安全性和探索性疗效研究：与促红细胞生成素α的比较
Am J Kidney Dis. 2016 Jun;67(6):912-24. doi: 10.1053/j.ajkd.2015.12.020. Epub 2016 Feb 2.
本文引用的文献
1
Efficacy and safety of darbepoetin alfa injection replacing epoetin alfa injection for the treatment of renal anemia in Chinese hemodialysis patients: A randomized, open-label, parallel-group, noninferiority phase III trial.在中国血液透析患者中，达贝泊汀α注射液替代促红细胞生成素α注射液治疗肾性贫血的疗效与安全性：一项随机、开放标签、平行组、非劣效性III期试验。
Chronic Dis Transl Med. 2022 Apr 18;8(2):134-144. doi: 10.1002/cdt3.23. eCollection 2022 Jun.
Zotero 插件